Dynavax Technologies Corp DVAX:NASDAQ

Last Price$12.86NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.29(2.21%)
Bid (Size)$12.74 (2)
Ask (Size)$12.88 (3)
Day Low / High$12.74 - 13.55
Volume2.4 M
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Dynavax Technologies Corp ( NASDAQ )

Price: $12.86
Change: -0.29 (2.21%)
Volume: 2.4 M
4:00PM ET 1/21/2022
 
 

Travere Therapeutics Inc ( NASDAQ )

Price: $25.57
Change: -0.13 (0.51%)
Volume: 474.0 K
4:00PM ET 1/21/2022
 
 

NanoString Technologies Inc ( NASDAQ )

Price: $32.59
Change: +0.25 (0.77%)
Volume: 956.5 K
4:00PM ET 1/21/2022
 
 

Morphic Holding Inc ( NASDAQ )

Price: $40.01
Change: -0.35 (0.87%)
Volume: 223.5 K
4:00PM ET 1/21/2022
 
 

Agios Pharmaceuticals Inc ( NASDAQ )

Price: $29.80
Change: -0.56 (1.84%)
Volume: 1.2 M
4:00PM ET 1/21/2022
 

Read more news Recent News

Dynavax Technologies Initiates Phase 1 Trial for Herpes Zoster Virus Vaccine Candidate
12:43PM ET 1/10/2022 MT Newswires

Dynavax Technologies (DVAX) said Monday it initiated a phase 1 clinical trial for its herpes zoster virus, also known as shingles, vaccine candidate,...

--Goldman Sachs Reinstates Dynavax Technologies at Buy With $38 Price Target
5:47AM ET 1/06/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--HC Wainwright Adjusts Price Target on Dynavax Technologies to $28 From $23, Reiterates Buy Rating
6:13AM ET 12/29/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

India Approves Merck's COVID-19 Pill Molnupiravir, Two Vaccines for Emergency Use
5:04AM ET 12/28/2021 MT Newswires

India approved Merck & Company's (MRK) COVID-19 pill molnupiravir and two other vaccines, Corbevax and Covovax, for emergency use, Minister of Health and...

View all Commentary and Analysis

New Strong Buy Stocks for January 21st
5:28AM ET 1/21/2022 Zacks

ARCB, BCC, DVAX, FCX, and JBHT have been added to the Zacks Rank #1 (Strong Buy) List on January...

Upward Earnings Estimate Revisions Screening Strategy
3:30AM ET 1/21/2022 Seeking Alpha

Dynavax: Vaccine Stalwart Coming Of Age
2:16AM ET 1/18/2022 Seeking Alpha

Dynavax: A Coronavirus Growth Story
8:00AM ET 1/17/2022 Seeking Alpha

Company Profile

Business DescriptionDynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA. View company web site for more details
Address2100 Powell Street
Emeryville, California 94608
Phone+1.510.848.5100
Number of Employees249
Recent SEC Filing12/14/20214
Chief Executive Officer & DirectorRyan Spencer
President & Chief Operating OfficerDavid F. Novack
Chief Financial Officer & Senior Vice PresidentKelly MacDonald
Chief Medical Officer & SVP-Clinical DevelopmentRobert Janssen

Company Highlights

Price Open$12.81
Previous Close$13.15
52 Week Range$4.99 - 21.39
Market Capitalization$1.5 B
Shares Outstanding120.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share$0.09
Beta vs. S&P 500N/A
Revenue$8.2 M
Net Profit Margin-14.89%
Return on Equity-50.34%

Analyst Ratings as of 01/19/2022

Buy
5
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset